FlowSyn fully integrates all the essential elements for flow chemistry into a single, user-friendly package, and was developed from concept to finished product in less than a year
Significant developments are reported by Uniqsis, the Cambridge-based joint venture company formed in January 2007 to develop a new concept in flow chemistry, leading to the launch of the FlowSyn continuous flow reactor at the end of last year.
The first systems are already in use in pharmaceutical development laboratories.
Uniqsis managing director Martyn Fordham said: "It's been an incredibly busy but rewarding year.
"The development team took FlowSyn from concept design and first prototype phases through to beta trial systems for pilot customers and now to the manufacture of fully standards-tested production models, and all in less than 12 months".
The FlowSyn technical team has also been given a real boost by the arrival of Mark Ladlow, a leading authority on flow chemistry.
Ladlow was until recently head of the GSK Cambridge Technology Laboratory based within the University of Cambridge, where in recent years he has collaborated closely with professor Steven Ley on developing flow chemistry as an emerging new chemistry technology.
Following a period as an independent consultant developing flow chemistry applications, he has now joined Uniqsis as chief scientific officer.
World-wide availability of FlowSyn is also expanding, with new distributors appointed in France, USA (Uniqsis will be exhibiting at Pittcon 2008), Italy and India.
